CN112243378B - 用于癌症免疫疗法的重组单纯疱疹病毒 - Google Patents

用于癌症免疫疗法的重组单纯疱疹病毒 Download PDF

Info

Publication number
CN112243378B
CN112243378B CN201980038180.3A CN201980038180A CN112243378B CN 112243378 B CN112243378 B CN 112243378B CN 201980038180 A CN201980038180 A CN 201980038180A CN 112243378 B CN112243378 B CN 112243378B
Authority
CN
China
Prior art keywords
cancer
hsv
cells
protein
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980038180.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN112243378A (zh
Inventor
何斌
刘星
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of CN112243378A publication Critical patent/CN112243378A/zh
Application granted granted Critical
Publication of CN112243378B publication Critical patent/CN112243378B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201980038180.3A 2018-06-08 2019-06-07 用于癌症免疫疗法的重组单纯疱疹病毒 Active CN112243378B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682202P 2018-06-08 2018-06-08
US62/682,202 2018-06-08
PCT/US2019/035922 WO2019236931A1 (en) 2018-06-08 2019-06-07 Recombinant herpes simplex virus for cancer immunotherapy

Publications (2)

Publication Number Publication Date
CN112243378A CN112243378A (zh) 2021-01-19
CN112243378B true CN112243378B (zh) 2024-12-31

Family

ID=67070913

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980038180.3A Active CN112243378B (zh) 2018-06-08 2019-06-07 用于癌症免疫疗法的重组单纯疱疹病毒

Country Status (8)

Country Link
US (2) US12329794B2 (https=)
EP (1) EP3801583B1 (https=)
JP (1) JP7373209B2 (https=)
KR (1) KR102906757B1 (https=)
CN (1) CN112243378B (https=)
AU (1) AU2019282755B2 (https=)
CA (1) CA3142073A1 (https=)
WO (1) WO2019236931A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111635913B (zh) * 2020-06-16 2022-03-04 广东东阳光药业有限公司 构建体及其应用
CN113862229A (zh) * 2020-06-30 2021-12-31 东莞市东阳光生物药研发有限公司 一种重组单纯疱疹病毒及其构建方法
CN113943752A (zh) * 2020-07-15 2022-01-18 东莞市东阳光生物药研发有限公司 构建体、敏感性提高的溶瘤病毒及其应用
CN114075574A (zh) * 2020-08-19 2022-02-22 广东东阳光药业有限公司 构建体、溶瘤病毒及其应用
TW202521570A (zh) * 2023-08-25 2025-06-01 大陸商勃林格殷格翰動物保健（中國）有限公司 用於禽類疫苗的新型ｄｅｖ載體

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60115600T2 (de) * 2000-01-21 2006-07-20 Biovex Ltd. Virusstämme für die onkolytische behandlung von krebs
US7264814B2 (en) * 2001-05-09 2007-09-04 M's Science Corporation Composition and method for treating cancer using herpes virus
GB0714578D0 (en) * 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses
ES2861450T3 (es) 2015-07-20 2021-10-06 Virttu Biologics Ltd Uso del virus del herpes simple oncolítico en combinación con un inhibidor de puntos de control inmunitario, en el tratamiento del cáncer
US20170319638A1 (en) 2016-05-06 2017-11-09 Virttu Biologics Limited Treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
An Engineered Herpesvirus Activates Dendritic Cells and Induces Protective Immunity;Yijie Ma等;Sci Rep.;20170202;摘要、第3页第3段、第5页第1-3段、第6页第2、4段 *
Antitumour actions of interferons: implications for cancer therapy;Belinda S. Parker等;Nature Reviews Cancer;20160225;第16卷(第3期);摘要、第131页左栏第1段、第132页最后一段至第133页第1段、图3、第136页左栏第2段至右栏第1段 *
Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications;DM Krisky等;Gene Therapy;19981231;第5卷(第11期);摘要 *
Effect of v34.5 deletions on oncolytic herpes simplex virus activity in brain tumors;Ryuichi Kanai等;Journal of Virology;20120215;第86卷(第8期);摘要、第4421页右栏第2段、第4429页左栏第1-2段 *

Also Published As

Publication number Publication date
US20250339482A1 (en) 2025-11-06
CN112243378A (zh) 2021-01-19
WO2019236931A1 (en) 2019-12-12
AU2019282755B2 (en) 2025-09-11
CA3142073A1 (en) 2019-12-12
US20210138009A1 (en) 2021-05-13
EP3801583A1 (en) 2021-04-14
AU2019282755A1 (en) 2021-01-28
KR20210022547A (ko) 2021-03-03
US12329794B2 (en) 2025-06-17
KR102906757B1 (ko) 2025-12-31
EP3801583B1 (en) 2025-07-02
JP7373209B2 (ja) 2023-11-02
JP2021527072A (ja) 2021-10-11

Similar Documents

Publication Publication Date Title
CN112243378B (zh) 用于癌症免疫疗法的重组单纯疱疹病毒
US12397053B2 (en) Engineered virus
Manservigi et al. HSV recombinant vectors for gene therapy
CN115820571B (zh) 一种重组单纯疱疹病毒及其用途
EP1381280B1 (en) Viral vectors and their use in therapeutic methods
Nguyen et al. The current state of oncolytic herpes simplex virus for glioblastoma treatment
Scanlan et al. Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers
US20210322545A1 (en) Smc combination therapy for the treatment of cancer
JPH10501990A (ja) 複製能力のある単純ヘルペスウイルスは新生細胞の破壊を媒介する
Zhang et al. Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR/Cas9 system for colon cancer treatment
CA3207359A1 (en) Adjuvant therapy for cancer
US20220064672A1 (en) Engineered oncolytic viruses expressing pd-l1 inhibitors and uses thereof
US7514252B2 (en) Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
JP4551042B2 (ja) ヘルペスγ３４．５遺伝子発現の細胞特異的および／または腫瘍特異的プロモーター再標的化
EP3594328A1 (en) Recombinant herpes simplex virus and use thereof
WO2000029033A2 (en) A method of genetic vector delivery
Froechlich Dissecting the STING-dependent molecular mechanisms in a preclinical model of combined treatment with tumour-targeted Herpes simplex virus and immune checkpoint blockade
Beauregard Type I Interferon-Mediated Killing of Cancer Cells with IAP-Targeted Combination Immunotherapy
Wongthida Understanding, and exploiting, the contribution of the immune system to the therapeutic efficacy of oncolytic virotherapy with vesicular stomatitis virus (VSV)
Gaston Potential roles of the immunostimulatory signals IL-15 and mica in oncolytic HSV-1 therapy for malignant glioma
Baird Development of a Novel Model for Exploring the Role of Regulatory T-cells in Oncolytic HSV Cancer Therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment